Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duacept
- Development stage
- Unknown
- Lead developer
- Arstat Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Duacept** is a small molecule oral contraceptive under development by **Arstat Pharmaceuticals**. It is specifically designed as a safer alternative to the leading European contraceptive pills for women of normal weight. The drug utilizes a **novel dosing regimen** intended to optimize efficacy while improving the safety profile compared to existing products. Duacept has received FDA endorsement for its clinical development program and is categorized as **Phase III-ready**, with Arstat Pharmaceuticals planning to initiate pivotal trials. It is part of a broader women's health pipeline that includes specialized contraceptives like Nuvocept (for overweight/obese women) and therapies for uterine conditions such as Premring and Enhanta.
- Brand names
- Duacept
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on Duacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duacept.